OverviewZogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$10.50 - 0.1
Data as of 02/24/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Investor Events More
Wednesday, February 22, 2017
Zogenix, Inc. at RBC Capital Markets Healthcare Conference
Wednesday, February 15, 2017 9:30 a.m. ET
Zogenix, Inc. at The LEERINK Partners 6th Annual Global Healthcare Conference